Neuromyelitis Optica Spectrum Disorder Market in Quarter 3 2025 Shows Strong Focus on Support Pathways and Education

Throughout Q3 2025, companies in the neuromyelitis optica spectrum disorder market distributed materials focused on brand access, as well as patient and HCP education and support.

Alexion presented a centralized pathway that supported treatment initiation through coordinated access and reduced administrative burden. Materials paired patient education resources with healthcare professional messaging that highlighted scientific presence at a major neurology congress.

Amgen introduced a centralized support framework, outlining coordinated enrollment steps and emphasizing patient education, peer connection, and ongoing access to resources.